The team's results, published in Nature Communications, reveal that the RMIT-patented biomarkers – easily identified through a simple blood test – may be a better guide to who'll potentially benefit ...

To address knowledge gaps, investigators conducted a meta-analysis of more than 70,000 patients in 10 trials of SGLT2 inhibitors vs placebo to determine the relative risks of CKD progression across ...

Nearly all adults with chronic kidney disease (CKD) would benefit from a systolic blood pressure (BP) target <12 ...